Mogamulizumab-kpkc Shows Strong Blood Response in Advanced CTCL

Treatment /

Treatment for cutaneous T-cell lymphoma (CTCL) is increasingly tailored to disease stage and location. Early-stage skin-only disease is often treated with phototherapy, while advanced disease may require systemic therapies such as romidepsin, pralatrexate, or Brentuximab vedotin. A key option for advanced CTCL is Mogamulizumab-kpkc, particularly for patients with high blood involvement or Sezary syndrome. In […]

Mogamulizumab-kpkc Shows Strong Blood Response in Advanced CTCL Read More »

Long-Term Japanese Study Confirms Safety and Effectiveness of Darbepoetin Alfa in MDS Anemia

Treatment /

A large real-world study in Japan has confirmed the long-term safety and effectiveness of Darbepoetin Alfa for treating anemia in patients with myelodysplastic syndromes (MDS). The 5-year post-marketing surveillance study followed 1,834 patients across 460 medical centers, providing much broader evidence than the original 2014 approval trial, which included only 52 patients. Researchers found that

Long-Term Japanese Study Confirms Safety and Effectiveness of Darbepoetin Alfa in MDS Anemia Read More »

New Immunotherapy and Targeted Drug Strategies Transform Bladder Cancer Treatment

Targeted Therapy /

Muscle-invasive bladder cancer (MIBC) treatment is undergoing major changes after nearly two decades of limited progress. Traditional treatment relied on surgery or radiation combined with cisplatin-based chemotherapy, but newer immunotherapies and targeted drugs are improving outcomes and reshaping care. Clinical trials have shown strong benefits from immune checkpoint inhibitors such as Nivolumab, Pembrolizumab, and Durvalumab.

New Immunotherapy and Targeted Drug Strategies Transform Bladder Cancer Treatment Read More »

EHMT2 inhibition Restores Chemotherapy Sensitivity in Colorectal Cancer by Reversing 5-FU Resistance

Research Advances /

A study published in Nature has identified a key epigenetic mechanism that drives resistance to 5-fluorouracil (5-FU) in colorectal cancer. Researchers found that increased activity of the enzyme EHMT2 leads to suppression of a tumor-suppressor gene called PPM1B, allowing cancer cells to survive chemotherapy and continue growing. The study showed that EHMT2 modifies gene expression

EHMT2 inhibition Restores Chemotherapy Sensitivity in Colorectal Cancer by Reversing 5-FU Resistance Read More »

Sacituzumab Tirumotecan Improves Survival in Advanced Endometrial Cancer Phase 3 Trial

Treatment /

The global phase 3 TroFuse-005 trial evaluated Sacituzumab Tirumotecan in 776 patients with advanced or recurrent endometrial cancer or carcinosarcoma whose disease had progressed after platinum-based chemotherapy and anti-PD-1/PD-L1 immunotherapy. The study compared the drug with physician’s choice chemotherapy, including doxorubicin or paclitaxel. Researchers reported that Sacituzumab Tirumotecan significantly improved both overall survival and progression-free

Sacituzumab Tirumotecan Improves Survival in Advanced Endometrial Cancer Phase 3 Trial Read More »

Enzalutamide Plus Radium-223 Shows Delayed Survival Benefit in mCRPC Trial

Clinical Trails /

An analysis of reconstructed individual patient data from the phase 3 EORTC 1333/PEACE-3 trial found that combining Enzalutamide with Radium-223 produced a delayed but meaningful long-term survival benefit in patients with metastatic castration-resistant prostate cancer (mCRPC). Researchers reported that the combination showed little survival advantage during the first 18 months of active treatment, but benefits

Enzalutamide Plus Radium-223 Shows Delayed Survival Benefit in mCRPC Trial Read More »

Annamycin Combination Shows Encouraging Remission Rates in Relapsed AML Trial

Clinical Trails /

Blinded results from Part A of the phase 2b/3 MIRACLE trial showed encouraging activity for Annamycin combined with Cytarabine in patients with relapsed or refractory Acute Myeloid Leukemia receiving second-line treatment. The study compared the combination with cytarabine plus placebo in patients aged 18 to 80. Among 45 evaluable patients, the pooled composite complete remission

Annamycin Combination Shows Encouraging Remission Rates in Relapsed AML Trial Read More »

Camrelizumab Plus Apatinib Shows Promising Activity in Refractory Chordoma Trial

Clinical Trails /

A phase 2 trial found that combining Camrelizumab and Apatinib showed promising results in patients with refractory chordoma, a rare and aggressive spine cancer. The study included 33 patients. The combination achieved an objective response rate of 24.2% by RECIST 1.1 and 48.5% by Choi criteria, with a disease control rate of 90.9%. Median progression-free

Camrelizumab Plus Apatinib Shows Promising Activity in Refractory Chordoma Trial Read More »

SunRISe-4 Analysis Identifies Biomarkers Linked to Response in Muscle-Invasive Bladder Cancer

Research Advances /

Researchers analyzing biomarkers from the phase 2 SunRISe-4 Trial found that high tumor mutational burden (TMB), genomic disease burden (GDB), and PD-L1 expression were linked to better pathologic overall response in patients with muscle-invasive bladder cancer (MIBC) receiving cisplatin-free neoadjuvant therapy. The study evaluated tissue and urine samples from 88 patients treated with a sustained

SunRISe-4 Analysis Identifies Biomarkers Linked to Response in Muscle-Invasive Bladder Cancer Read More »

Pluvicto Improves PSA Responses in Metastatic Hormone-Sensitive Prostate Cancer in PSMAddition Trial

Clinical Trails /

Results from the phase 3 PSMAddition trial showed that adding lutetium Lu 177 vipivotide tetraxetan (Pluvicto) to androgen-deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI) improved prostate-specific antigen (PSA) responses in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The randomized phase 3 study included 1,144 men with PSMA-positive mHSPC. Patients received either Pluvicto

Pluvicto Improves PSA Responses in Metastatic Hormone-Sensitive Prostate Cancer in PSMAddition Trial Read More »